PSivida plans to resubmit NDA for Illuvien drug-device combo

03/28/2013 | (Boston)

PSivida said it will refile a new drug application for Illuvien, which is used to treat patients with diabetic macular edema, by month's end. The drug/device combination, which is licensed to Alimera Sciences, was originally rejected by the FDA in 2011 after a clinical trial failed to prove that the product's benefits surpass the potential risks.

View Full Article in: (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC